Bionano Share Based Compensation vs Issuance Repayment of Debt Securities Analysis
BNGO Stock | USD 1.09 0.05 4.81% |
Trend analysis of Bionano Genomics balance sheet accounts such as Short Long Term Debt Total of 92.3 M, Other Current Liabilities of 8.9 M or Total Current Liabilities of 105 M provides information on Bionano Genomics' total assets, liabilities, and equity, which is the actual value of Bionano Genomics to its prevalent stockholders. By breaking down trends over time using Bionano Genomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Bionano |
About Bionano Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Bionano Genomics at a specified time, usually calculated after every quarter, six months, or one year. Bionano Genomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bionano Genomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bionano currently owns. An asset can also be divided into two categories, current and non-current.
Bionano Genomics Balance Sheet Chart
Bionano Genomics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bionano Genomics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Bionano Genomics' Net Debt is very stable compared to the past year. As of the 28th of March 2024, Cash is likely to grow to about 55.7 M, while Total Assets are likely to drop about 142.9 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Bionano Genomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bionano Genomics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Bionano Genomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bionano Genomics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Bionano Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Tax Provision is very stable compared to the past year. As of the 28th of March 2024, Selling General Administrative is likely to grow to about 98.2 M, while Enterprise Value Multiple is likely to drop (0.83).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 927K | 298K | 5.1M | 5.4M | Depreciation And Amortization | 177K | 1.3M | 13.7M | 14.4M |
Bionano Genomics fundamental ratios Correlations
Click cells to compare fundamentals
Bionano Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bionano Genomics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 30.2M | 60.4M | 377.1M | 307.5M | 214.4M | 142.9M | |
Short Long Term Debt Total | 20.0M | 16.3M | 10.7M | 11.7M | 87.9M | 92.3M | |
Other Current Liab | 3.2M | 5.6M | 9.7M | 19.9M | 8.1M | 8.9M | |
Total Current Liabilities | 26.3M | 8.9M | 21.8M | 35.9M | 100.0M | 105.0M | |
Total Stockholder Equity | 3.6M | 35.1M | 337.1M | 249.4M | 96.2M | 89.9M | |
Other Liab | 227.1K | 97.9K | 9.2M | 13.1M | 15.1M | 15.8M | |
Net Tangible Assets | 3.6M | 26.4M | 337.1M | 172.1M | 197.9M | 207.8M | |
Property Plant And Equipment Net | 1.9M | 4.9M | 20.9M | 29.0M | 32.5M | 34.1M | |
Current Deferred Revenue | 357.5K | 415.5K | 684K | 871K | 783K | 555.6K | |
Net Debt | 2.7M | (22.1M) | (13.9M) | 6.6M | 34.9M | 36.6M | |
Retained Earnings | (102.6M) | (143.7M) | (216.1M) | (348.7M) | (581.2M) | (552.1M) | |
Accounts Payable | 2.7M | 2.9M | 9.7M | 12.5M | 10.4M | 5.9M | |
Cash | 17.3M | 38.4M | 24.6M | 5.1M | 53.1M | 55.7M | |
Non Current Assets Total | 1.9M | 13.7M | 104.7M | 150.2M | 74.3M | 48.6M | |
Non Currrent Assets Other | (1.9M) | 102.6K | 749K | 2.8M | 7.4M | 7.8M | |
Cash And Short Term Investments | 17.3M | 38.4M | 250.6M | 113.2M | 101.9M | 74.8M | |
Net Receivables | 6.3M | 2.8M | 4.9M | 7.0M | 9.7M | 5.6M | |
Common Stock Total Equity | 3.4K | 19.0K | 29K | 30K | 34.5K | 36.2K | |
Common Stock Shares Outstanding | 1.5M | 10.4M | 27.7M | 28.9M | 34.2M | 35.9M | |
Liabilities And Stockholders Equity | 30.3M | 60.4M | 377.1M | 307.5M | 214.4M | 142.9M | |
Non Current Liabilities Total | 335.0K | 16.4M | 18.1M | 22.2M | 18.2M | 16.2M | |
Capital Surpluse | 106.2M | 178.7M | 553.7M | 599.2M | 689.1M | 723.5M | |
Inventory | 3.4M | 3.3M | 12.4M | 29.8M | 22.9M | 24.0M | |
Other Current Assets | 1.2M | 2.2M | 4.5M | 7.3M | 5.7M | 3.2M | |
Other Stockholder Equity | 106.2M | 178.7M | 553.7M | 599.2M | 677.3M | 711.2M | |
Total Liab | 26.6M | 25.4M | 40.0M | 58.1M | 118.2M | 124.2M | |
Property Plant And Equipment Gross | 1.9M | 4.9M | 10.3M | 29.0M | 51.6M | 54.1M | |
Total Current Assets | 28.3M | 46.8M | 272.4M | 157.3M | 140.1M | 94.3M | |
Accumulated Other Comprehensive Income | (5.2M) | (6.3M) | (539K) | (1.1M) | 23K | 24.2K | |
Non Current Liabilities Other | 808.4K | 44.5K | 18.0M | 22.1M | 10.9M | 8.4M | |
Common Stock | 3.4K | 19.0K | 29K | 30K | 5K | 4.8K | |
Property Plant Equipment | 1.9M | 4.9M | 10.3M | 18.0M | 20.7M | 21.8M | |
Net Invested Capital | 23.7M | 51.4M | 337.1M | 249.4M | 166.0M | 126.2M | |
Net Working Capital | 1.9M | 37.8M | 250.6M | 121.4M | 40.1M | 72.4M | |
Retained Earnings Total Equity | (102.6M) | (143.7M) | (216.1M) | (348.7M) | (313.8M) | (298.2M) | |
Deferred Long Term Liab | 182.6K | 97.9K | 146K | 127K | 114.3K | 137.3K |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
0.76 | MBRX | Moleculin Biotech Upward Rally | PairCorr |
0.8 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Bionano Stock
0.78 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.72 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.68 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Bionano Stock analysis
When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.81) | Revenue Per Share 1.058 | Quarterly Revenue Growth 0.305 | Return On Assets (0.33) | Return On Equity (1.35) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.